Economic Benefits

The best source of determining the potential economic benefits of BioHuntress can be gauged by identifying product sales for similar blood cancer treatment drugs. For example, Revlimid alone accounts for 65% of Celgene’s revenue, generating US $23.7 billion dollars of their total net sales of US $37.36 billion dollars in 2018. In North America, it is unfortunate that there are about 16.6 million cancer patients encompassing 1.4 million blood cancer patients. Annually, around US $162 billion is being spent on chemotherapy treatments such as Revlimid for these patients. If the target market of BioHuntress is 5% of the patients that sign-up for clinical trials, this will lead to an $8 billion dollars.

In Oct 2020-May 2021, BioHuntress has gained enormous traction by graduating from the Creative Destruction Labs (CDL Atlantic, Halifax) program and participating at the international Super Session (https://www.creativedestructionlab.com/locations/halifax/). The program of CDL-Atlantic prime is a highly competitive, objectives-based program for massively scalable, seed-stage, science- and technology-based companies. BioHuntress has received the valuable mentorship/guidance from both the CDL Halifax and Vancouver site mentors. Among a well-rounded group of advisors, Dr. Julia Levy is the Founder and Director Emerita of QLT Inc.; the only Canadian based company to have discovered and led the development of a successful drug independently and that once had a valuation higher than some Canadian banks. Dr. Levy remains actively involved in mentoring and investing in early-stage life sciences ventures and currently serves as an advisor to BioHuntress.

BioHuntress has a valuable IP portfolio with access to three compounds (patent issued / patent filed) that have been scientifically validated at two advanced biotechnology research laboratories; Dalhousie Medicine New Brunswick and the University of New Brunswick. These compounds have been inspired by natural compounds and are on track to be developed into superior, safer treatments than those that are currently being offered for blood cancers. BioHuntress has gained the legitimacy of MITACS and BioNova for its innovations and ideas – Dr. Murugesan/BioHuntress has gained the legitimacy of MITACS by receiving the 2018 MITACS Global Impact Entrepreneur Award – a national recognition for outstanding innovation in cancer research, and entrepreneurship and that of BioNova by being the semi-finalists at the BioNova’s BioInnovation Challenge in 2018.